Business
Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments
WALTHAM, Mass., July 30, 2025--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that it has entered into an exclusive collaboration and license agreement with Kissei Pharmaceutical Co., Ltd. ("Kissei") to develop and commercialize veligrotug and VRDN-003 in Japan. Both molecules are anti-insulin-like growth factor-1 receptor (IGF-1R) anti
About this update from Kissei Pharmaceutical Co., Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2400,"height":600,"url":"https://media.zenfs.com/en/business-wire.com/eedb2e55c062f9ae0c904066f41b3dce"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2prKTATtWMqpJlr6rwBzhw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/eedb2e55c062f9ae0c904066f41b3dce","width":960,"height":240},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/LanxJRTHDP.X0S6RX7M.1A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/eedb2e55c062f9ae0c904066f41b3dce","width":1200,"height":300}},"lazy":false},{"type":"text","content":"- Kissei obtains an exclusive license to develop and commercialize veligrotug and VRDN-003 in Japan -","length":101,"tagName":"p","attribs":{}},{"type":"text","content":"- Viridian to receive an upfront payment of $70 million -","length":57,"tagName":"p","attribs":{}},{"type":"text","content":"- Additionally, Viridian is eligible to receive up to an additional $315 million in development, regulatory, and commercial milestone payments as well as tiered royalties on net sales in Japan in the 20s to mid-30s percent -","length":224,"tagName":"p","attribs":{}},{"type":"text","content":"- Collaboration combines Viridian’s potential best-in-class portfolio in thyroid eye disease with Kissei’s development and commercialization expertise in rare diseases in Japan -","length":178,"tagName":"p","attribs":{}},{"type":"text","content":"WALTHAM, Mass., July 30, 2025--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that it has entered into an exclusive collaboration and license agreement with Kissei Pharmaceutical Co., Ltd. ("Kissei") to develop and commercialize veligrotug and VRDN-003 in Japan. Both molecules are anti-insulin-like growth factor-1 receptor (IGF-1R) antibodies for the potential treatment of patients with thyroid eye disease (TED), and VRDN-003 is a potential best-in-class, subcutaneous, half-life extended anti-IGF-1R antibody with the same binding domain as veligrotug. TED is an autoimmune condition characterized...